Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736620 | 1.00 | NPC1 (0.54) | NPC1MEN1KMT2ASCN9ASCN3A | |
| SCHEMBL628425 | 1.00 | NPC1 (0.54) | NPC1MEN1KMT2ASCN9ASCN3A | |
| SCHEMBL13125097 | 0.92 | NPC1 (0.63) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13125335 | 0.89 | NPC1 (0.59) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13125332 | 0.86 | NPC1 (0.54) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13150256 | 0.85 | NPC1 (0.61) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13125030 | 0.83 | NPC1 (0.65) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13125065 | 0.83 | NPC1 (0.65) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13125458 | 0.83 | NPC1 (0.55) | NPC1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL13125098 | 0.83 | SCN3A (0.45) | SCN9ASCN3AHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPC1 81/4885MEN1 4681/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.